With the aim of identifying metabolites potentially useful to discriminate PCa from BPH, we analyzed plasma of subjects with PSA ranging from 4 to 16 ng/ml, within a cohort of consecutively recruited patients who underwent prostate biopsy. The gene discussed is KLK3; the disease is posterior cortical atrophy.